Nasdaq-listed VectivBio Holding, a clinical-stage biopharmaceutical company, has priced an underwritten offering of 16,700,000 ordinary shares at US$7.50 per share, raising US$125m in gross proceeds. Investors agreeing to underwrite the…
Nasdaq-listed VectivBio Holding, a clinical-stage biopharmaceutical company, has priced an underwritten offering of 16,700,000 ordinary shares at US$7.50 per share, raising US$125m in gross proceeds. Investors agreeing to underwrite the…
…
Rankings & Reports
M&A
Equity
Healthcare Investing Review
Healthcare Real Assets Report
Resources & Events
Resource Hub
Sector Events
Private Capital Conference
Real Assets Conference